Search This Board: 
Created: 06/28/2013 11:06:32 AM - Followers: 14 - Board type: Free - Posts Today: 0

Jun 9, 2014
iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
May 29, 2014
iCo Therapeutics Announces First Quarter 2014 Financial Results
Apr 29, 2014
iCo Therapeutics Announces Poster Presentation at ARVO

View All News (+)




iCo Therapeutics Inc. (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Management strength is supported by an impressive group of Directors and Advisors.

There is a significant decrease in development risk associated with targeting existing drugs, including:

  • Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
  • Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
  • The target and mechanism of action has been identified.



iCo Therapeutics is developing iCo-007, a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA), for the treatment of retinal neovascular diseases such as diabetic retinopathy (including diabetic macular edema). These conditions are characterized by new blood vessel growth and increased vascular permeability. Drug products that prevent the growth of new blood vessels and inhibit increased vascular permeability may have the potential to treat neovascular diseases, including diabetic retinopathy and diabetic macular edema.  Read More +


iCo-008 (also known as Bertilimumab or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins, that acts as messenger molecules between the cells of the immune system.

Eotaxin-1 is released by various cells, including eosinophils, epithelial cells, fibroblasts, endothelial cells, T-lymphocytes, monocytes and macrophages. During an allergic response the levels of eotaxin-1 are elevated. This attracts eosinophils, a type of white blood cell, into tissues where they can degranulate causing tissue damage that occurs in a variety of allergic disorders. This condition, known as eosinophilia, can occur in a number of disorders, such as allergic ocular disease of conjunctiva and cornea (conjunctivitis and keratoconjunctivitis), asthma, allergic rhinitis, atopic dermatitis, and other inflammatory disorders, such as inflammatory bowel disease and Crohn's disease.  Read More +

Oral Amphotericin B Delivery System

iCo Therapeutics owns the worldwide exclusive rights to an oral Amphotericin B delivery system for life-threatening infections. The drug delivery technology also has the potential to reprofile other IV administered drugs to the oral route of administration.

Amphotericin B (AmpB), the gold standard for systemic antifungal drugs, is one example of a well established, highly efficacious systemic antifungal drug that has a 50 year history of intravenous therapy. AmpB formulated as a micellar dispersion (Fungizone® FZ) for IV use, remains one of the most effective agents in the treatment of systemic fungal infections, yet no oral formulations are currently commercially availableRead More +


Alliances & Global Licensing


iCo is actively looking to identify and acquire the rights to products that have a previous clinical history with potential for ophthalmic uses. iCo then employs various drug delivery technologies, re-doses or reformulates these existing products in order to enable ocular administration and gain additional intellectual property coverage for the product. This strategy enables partners to maximize the value of their existing assets with minimal risk of cross use / cross pricing issues.

iCo Therapeutics is currently engaged in partnership arrangements with organizations that include Isis Pharmaceuticals, MedImmune, Immune Pharmaceuticals, AstraZeneca and the University of British Columbia.

iCo Therapeutics acquired the exclusive, world-wide rights from partner Isis Pharmaceuticals Inc., to develop and commercialize iCo-007 for all disease indications. 

iCo has a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema (DME).

From partner MedImmune (a division of Astra Zeneca), iCo Therapeutics acquired the exclusive, world-wide rights to develop and commercialize iCo-008 for all disease indications.  In 2010, iCo granted Immune Pharmaceuticals an option to an exclusive license for the development and commercialization rights to the systemic uses of iCo-008. Immune Pharmaceuticals licensed the systemic rights to iCo-008 in June 2011. iCo retained worldwide exlcusive rights to all ocular applications of iCo-008.  The partnership with the University of British Columbia resulted in the acquisition of the exclusive, worldwide rights to a novel oral formulation for Amphotericin B to be used for potential systemic fungal and parasitic infections.    

Investor Relations

iCo was awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and is a Canada's Top 10™ Competition winner.  

iCo trades on the TSX Venture Exchange under the symbol "ICO", and the OTCQX under the symbol “ICOTF”.


iCo Finance: John Meekison, CFO.  604-602-9414

Equicom Group: Michael Moore, Investor Relations 858-886-7813

Fact Sheets

Corporate Fact sheet

iCo-007 Fact sheet

iCo-008 Fact sheet

Oral Amphotericin B Delivery System Fact sheet

ICOTF Security Details
Share Structure
Market Value1 $5,067,463 a/o Jun 13, 2014
Shares Outstanding 84,457,713 a/o May 29, 2014
Float 62,821,290 a/o Nov 21, 2013
Authorized Shares Unlimited a/o Nov 21, 2013
Par Value No Par Value

Shareholders of Record Not Available
Non US Stock Exchange Listing
ICO - TSX Venture Exchange - Qualified

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
News on the go ! Oloo 04/14/2022 10:28:13 AM
On the way for a lead candidate: Oloo 03/31/2022 12:53:10 PM
Awesome thing coming soon ! Oloo 12/14/2021 10:09:15 AM
Effective Dec. 10,2021 ICOTF will change to MSCLF. Renee 12/09/2021 10:04:03 AM
As soon as FINRA posts the official ticker Renee 08/18/2021 11:06:36 AM
New ticker - MSCL - I use TD Dapper1 08/18/2021 10:41:17 AM
ICOTF: effective Aug. 18,2021 Ico Therapeutics Inc. will Renee 08/17/2021 07:50:03 AM
Newsfile Corp. Dapper1 07/12/2021 09:29:29 PM
#171 Wait for the next press release. We will Oloo 03/25/2021 02:14:12 PM
#170 Voting No on this deal is crucial. Ico boston79 03/24/2021 12:28:51 PM
#169 Easy $1.00 that’s only $152 million market cap, boston79 03/03/2021 10:02:54 AM
#168 Hello. What’s everyone’s price per share target here, J_Dean 03/02/2021 04:11:23 PM
#167 CB-DT run imminent. Ico is a covid play boston79 02/24/2021 12:50:51 PM
#166;year=2020;volume=15; boston79 02/18/2021 09:53:04 PM
#165 Someone’s front loading milllions of shares. Could be boston79 02/18/2021 10:57:42 AM
#164 Ya it’s a covid play now. This stock boston79 02/18/2021 09:21:11 AM
#163 Something going on! Oloo 02/14/2021 04:32:32 PM
#162 It's here WoW Mikefbi 01/25/2021 09:52:31 AM
#161 “Acceleration event” in the dec 1. Filing indicates boston79 12/08/2020 07:22:40 AM
#160 Big move coming $$$$$ boston79 12/08/2020 06:59:43 AM
#159 Mike what are thinking about this stock and kratz 10/08/2020 01:39:41 PM
#158 I when should we hear something positive kratz 05/13/2020 08:24:41 PM
#157 Real partners Mikefbi 05/12/2020 07:10:09 PM
#156 Why kratz 05/12/2020 04:41:44 PM
#155 I believe this is a long term winner Mikefbi 05/10/2020 01:29:14 AM
#154 Still believe it's a great long term investment Mikefbi 04/21/2020 03:22:24 PM
#153 iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo Jabramowitz 04/17/2020 08:23:05 AM
#152 Alexion is obligated to pay them $32m to Jabramowitz 03/26/2020 07:21:58 AM
#151 Still believe it might and should benefit from BrianSkidless 03/25/2020 02:53:58 PM
#150 yes sir Jabramowitz 03/25/2020 02:46:17 PM
#149 You're still holding this? BrianSkidless 03/16/2020 05:25:30 PM
#148 iCo Therapeutics Announces Completion of Phase 1b Oral Jabramowitz 02/10/2020 09:38:36 AM
#147 from Alexion website: Jabramowitz 01/27/2020 09:49:21 AM
#146 some folks on the IMNP chat room still Jabramowitz 01/27/2020 09:45:01 AM
#145 they were chasing some shares on Tuesday the Jabramowitz 01/02/2020 12:20:43 PM
#144 Should be a very good investment Mikefbi 12/31/2019 10:16:30 PM
#143 iCo Therapeutics Announces Completion of Sub-license Transfer and Jabramowitz 12/24/2019 09:53:59 AM
#142 Phase 2 Bertilimumab Trial Jabramowitz 12/12/2019 12:10:39 PM
#141 Vancouver, British Columbia--(Newsfile Corp. - December 11, 2019) Jabramowitz 12/12/2019 12:03:39 PM
#140 Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) Jabramowitz 12/12/2019 11:59:45 AM
#139 Continue to buy for the long term Mikefbi 12/11/2019 02:47:52 PM
#138 Looking good continue to buy based on Mikefbi 12/07/2019 01:15:22 PM
#137 News: $ICOTF iCo Therapeutics Announces Third Quarter 2019 whytestocks 12/02/2019 12:00:39 PM
#136 What's the deal here? tmeier 12/01/2019 07:53:16 PM
#135 Solid investment right here..when people find this, it Nostockdamus26 11/27/2019 10:07:13 AM
#134 Alexion Pharmaceuticals - iCo's New Partner for the Nostockdamus26 11/27/2019 10:06:15 AM
#133 Anyone notice the volume spike and 15% gain Dapper1 10/12/2019 05:15:52 PM
#132 Rumor of something coming... atomicnumber31 03/27/2019 03:27:30 PM
#131 Going back on track ?? Climer58 08/08/2018 12:13:56 PM
#130 Last week 0.19 and Now 0.07???? Climer58 07/26/2018 12:48:52 AM
Post Subject